BioMed Research International / 2009 / Article / Tab 1

Research Article

OXavidin for Tissue Targeting Biotinylated Therapeutics

Table 1

Setting up production method of OXavidin.

NaIO4 mMCHO/Avidin molar ratio SDST2210 binding SDTissue residence % ID/100 mg SD
( )( )24 hours ( )1 week ( )

Avidin LoQ 002.2 0.40.5 0.1
(5)(7)(5)

Oxidized avidin15.6 0.877.2 0.93.1 0.70.16 0.03
(5)(4)(1)(1)
57.5 0.855.7 2.26.3 0.30.99 0.25
(5)(4)(1)(1)
108.4 1.050.9 2.418.0 2.59.7 3.2
(6)(6)(4)(3)
2011.5 1.5*49.1 2.119.1 2.011.4 1.3
(7)(6)(4)(3)
4010.9 2.644.5 0.9NTNT
(5)(4)

HABA

OXavidin14.0 0.899.0 0.2NTNT
(3)(3)
57.1 1.695.0 1.7NTNT
(4)(3)
108.5 1.386.3 ±1.6**16.2 ±2.39.9 ±1.3
(5)(3)(4)(4)
2012.9 2.3#81.4 1.0#**18.7 1.111.7 1.7
(6)(4)(5)(5)
409.8 1.973.0 0.6NTNT
(4)(3)

: Number of independent experiments; SD: Standard Deviation; NT: Not tested.
@The experimental value of 97.4 0.5% obtained with ST2210 compared to free biotin by HABA assay is assumed as 100% reference value for modified avidins; versus 10 mM; versus 10 mM (One way Anova followed by Student-Newman-Keuls); versus same without HABA (Two-way Anova followed by Bonferroni).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.